Clinical Trial Update: Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

Phase 3 trial update for ALXN1720 evaluating safety and efficacy in adults with Generalized Myasthenia Gravis; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• ALXN1720

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: ACTIVE_NOT_RECRUITING